Trial
NCT05179603
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
Merck Sharp & Dohme LLC
Condition
Classic Hodgkin Lymphoma
Intervention
THOR-707
Why stopped
Early discontinuation based on strategic sponsor decision not driven by any safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-24